ABSTRACT
Objective Hirschsprung disease (HSCR) is a severe congenital disorder affecting 1:5000 live births. HSCR results from failure of enteric nervous system (ENS) progenitors to fully colonise the gastrointestinal tract during embryonic development. This leads to aganglionosis in the distal bowel, resulting in disrupted motor activity and impaired peristalsis. Currently, the only viable treatment option is surgical resection of the aganglionic bowel. However, patients frequently suffer debilitating, lifelong symptoms, with multiple surgical procedures often necessary. Hence, alternative treatment options are crucial. An attractive strategy involves the transplantation of ENS progenitors generated from human pluripotent stem cells (hPSCs).
Design ENS progenitors were generated from hPSCs using an accelerated protocol and characterised, in detail, through a combination of single cell RNA-sequencing, protein expression analysis and calcium imaging. We tested ENS progenitors’ capacity to integrate and restore functional responses in HSCR colon, after ex vivo transplantation to organotypically cultured patient-derived colonic tissue, using organ bath contractility.
Results We found that our protocol consistently gives rise to high yields of cell populations exhibiting transcriptional and functional hallmarks of early ENS progenitors. Following transplantation, hPSC-derived ENS progenitors integrate, migrate and form neurons within explanted human HSCR colon samples. Importantly, the transplanted HSCR tissue displayed increased basal contractile activity and increased responses to electrical stimulation compared to control tissue.
Conclusion Our findings demonstrate, for the first time, the potential of hPSC-derived ENS progenitors to repopulate and restore functional responses in human HSCR patient colonic tissue.
What is already known on this topic
Hirschsprung disease is a devastating condition characterized by aganglionosis of the enteric nervous system (ENS) in the distal bowel, leading to dysmotility, severe constipation and enterocolitis.
Stem cell therapy offers the potential to generate an enteric nervous system in aganglionic tissue and previous studies have described methods for generating ENS progenitors.
However, the ability of these cells to establish intestinal motility in HSCR human tissue has not been shown.
What this study adds
We describe, for the first time, the detailed characterization of an ENS progenitor population derived from human pluripotent stem cell lines using our efficient protocol.
Further, we demonstrate the ability of ENS progenitors to differentiate into enteric neurons in vitro and mediate functional rescue following transplantation into explants of human Hirschsprung disease tissue.
How this study might affect research, practice or policy
These results clearly show the potential of hPSC-derived ENS progenitors in stem cell therapy of Hirschsprung disease for progression towards clinical trials.
This study highlights the significant advantages of using human surgical discard tissue for testing the efficacy of stem cell therapies.
The described ex vivo model can be used to test different therapeutic approaches prior to clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the MRC (MR/V002163/1; AT, CMC, PWA, PDC, NT), European Union Horizon 2020 Framework Programme (H2020-EU.1.2.2; project 824070; AT, PWA, PVB) and NC3Rs (NC/V001078/1; CMC)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of London Bloomsbury gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
